New System Boosted Lung Cancer Surgery by 43% in Black Patients
A unique real-time warning system increased timely lung cancer surgery by identifying patients who were at risk of dropping out of treatment.
Source: medscape.com
📰 Nsclc News
Page 49 - Nsclc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nsclc. Real-time updates on events, politics, business and more.
Roche's Tecentriq Gets EC Nod As Adjuvant Treatment For Certain People With Early-stage NSCLC
SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG's (RHHBY) blockbuster drug Tecentriq has been approved by the European Commission for yet another lung cancer indication - this time, as an adjuvant
United Kingdom Levi Garraway European Commission Head Of Global Product Development Roche Holding Chief Medical Officer
Source: finanznachrichten.de
Four Poster Presentations at 2022 ASCO Annual Meeting
NSCLC Atalante-1 Phase 3 Trial Beyond Checkpoint Inhibitor Neoepitope Specific Immunotherapy Tedopi® Shows Significant Patient-Reported Outcomes Versus ChemotherapyPositive Interim Results in... | June 7, 2022
Source: marketscreener.com
Adagrasib Shows Durable Benefit in KRAS-Mutated NSCLC
Adagrasib shows durable clinical benefit in previously treated, advanced KRASG12C-mutated non-small cell lung cancer, including patients with brain metastases.
New York United States Joshua Sabari American Society For Clinical Oncology Drug Administration Perlmutter Cancer Center
Source: medscape.com
Cantargia AB: Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC
STOCKHOLM, May 26, 2022 /PRNewswire/ -- Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported updated interim results for non-small cell lung cancer (NSCLC) patients treated with
Source: finanznachrichten.de
Quitting Smoking Even After Lung Cancer Diagnosis Worth Doing
Accumulating data show that patients who quit smoking at or around the time they are diagnosed with lung cancer live longer than those who continue to smoke.
United States Saverio Caini William Evans Mcmaster University Clinical Network Institute For Cancer Research
Source: medscape.com
Promising Antitumor Activity After One ADC Dose in Breast Cancer
Early data suggest that the antibody drug conjugate patritumab deruxtecan increases antitumor activity in early-stage breast cancer after a single dose.
Comunidad Autonoma De Cataluna Daiichi Sankyo Aleix Prat Oncology Department Of Hospital Cl National Cancer Center Oncology Department
Source: medscape.com
EU OK for New Drugs for Lung Cancer and Follicular Lymphoma
Capmatinib for lung cancer and mosunetuzumab for follicular lymphoma have been recommended for approval in the European Union.
United States European Union European Commission Drug Administration European Medicine Agency Committee For Medicinal Products Human Use
Source: medscape.com
New Trials in Lung Cancer: Could Your Patients Benefit?
Several studies in lung cancer have started enrolling recently ― maybe one of your patients could benefit.
Source: medscape.com
'Major Advance': Sotorasib Benefit Persists in KRAS+ NSCLC
The first-in-class KRAS inhibitor showed durable benefit in some patients, but emergence of early resistance requires new combination therapies, investigators say.
Source: medscape.com